Adrienne M Flanagan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3751498/publications.pdf

Version: 2024-02-01

164 papers	25,290 citations	19657 61 h-index	6996 154 g-index
174 all docs	174 docs citations	174 times ranked	31617 citing authors

#	Article	IF	Citations
1	Mutations of the BRAF gene in human cancer. Nature, 2002, 417, 949-954.	27.8	9,374
2	Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development. Cell, 2011, 144, 27-40.	28.9	2,020
3	IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. Journal of Pathology, 2011, 224, 334-343.	4.5	834
4	Intragenic ERBB2 kinase mutations in tumours. Nature, 2004, 431, 525-526.	27.8	757
5	Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nature Genetics, 2013, 45, 1479-1482.	21.4	667
6	Somatic Mutations of the Protein Kinase Gene Family in Human Lung Cancer. Cancer Research, 2005, 65, 7591-7595.	0.9	429
7	Kaposi sarcoma herpesvirusâ€"induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nature Genetics, 2004, 36, 687-693.	21.4	414
8	Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nature Genetics, 2011, 43, 1262-1265.	21.4	368
9	Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. European Journal of Cancer, 2019, 109, 36-50.	2.8	354
10	Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. Science, 2014, 345, 1251343.	12.6	348
11	A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nature Genetics, 2005, 37, 590-592.	21.4	318
12	Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. ELife, 2014, 3, .	6.0	318
13	Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nature Genetics, 2014, 46, 376-379.	21.4	269
14	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	12.8	237
15	In ovarian neoplasms,BRAF, but notKRAS, mutations are restricted to low-grade serous tumours. Journal of Pathology, 2004, 202, 336-340.	4.5	229
16	Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers. Clinical Cancer Research, 2004, 10, 2473-2481.	7.0	224
17	Brachyury Expression in Extra-axial Skeletal and Soft Tissue Chordomas: A Marker that Distinguishes Chordoma From Mixed Tumor/Myoepithelioma/Parachordoma in Soft Tissue. American Journal of Surgical Pathology, 2008, 32, 572-580.	3.7	223
18	Mutational signatures of ionizing radiation in second malignancies. Nature Communications, 2016, 7, 12605.	12.8	214

#	Article	IF	Citations
19	Chloride Channel ClCN7 Mutations Are Responsible for Severe Recessive, Dominant, and Intermediate Osteopetrosis. Journal of Bone and Mineral Research, 2003, 18, 1740-1747.	2.8	202
20	Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nature Genetics, 2013, 45, 799-803.	21.4	181
21	Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nature Genetics, 2013, 45, 923-926.	21.4	180
22	Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma. Nature Communications, 2017, 8, 15936.	12.8	179
23	Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functionalâ€based study. Journal of Pathology, 2011, 223, 327-335.	4.5	174
24	Use of cancerâ€specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes and Cancer, 2010, 49, 1062-1069.	2.8	172
25	Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma. Modern Pathology, 2007, 20, 482-496.	5.5	168
26	DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology, 2010, 57, 259-270.	2.9	162
27	Inhibition of bone resorption by bisphosphonates: Interactions between bisphosphonates, osteoclasts, and bone. Calcified Tissue International, 1991, 49, 407-415.	3.1	157
28	The multinucleate cells in giant cell granulomas of the jaw are osteoclasts. Cancer, 1988, 62, 1139-1145.	4.1	156
29	Signatures of copy number alterations in human cancer. Nature, 2022, 606, 984-991.	27.8	154
30	H3F3A (Histone 3.3) G34W Immunohistochemistry. American Journal of Surgical Pathology, 2017, 41, 1059-1068.	3.7	153
31	Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2. Nature Communications, 2013, 4, 2166.	12.8	152
32	The Gene for Cherubism Maps to Chromosome 4p16.3. American Journal of Human Genetics, 1999, 65, 151-157.	6.2	145
33	Chromosome segregation errors generate a diverse spectrum of simple and complex genomic rearrangements. Nature Genetics, 2019, 51, 705-715.	21.4	145
34	Anti-MuÌˆllerian Hormone Protein Expression Is Reduced during the Initial Stages of Follicle Development in Human Polycystic Ovaries. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5536-5543.	3.6	144
35	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. JAMA Oncology, 2020, 6, 724.	7.1	139
36	Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclastâ€rich mimics. Journal of Pathology: Clinical Research, 2015, 1, 113-123.	3.0	135

#	Article	IF	Citations
37	Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors. Science, 2018, 361, .	12.6	121
38	A molecular map of mesenchymal tumors. Genome Biology, 2005, 6, R76.	9.6	119
39	The driver landscape of sporadic chordoma. Nature Communications, 2017, 8, 890.	12.8	115
40	A common single-nucleotide variant in T is strongly associated with chordoma. Nature Genetics, 2012, 44, 1185-1187.	21.4	112
41	MRI characteristics of lipoma and atypical lipomatous tumor/well-differentiated liposarcoma: retrospective comparison with histology and MDM2 gene amplification. Skeletal Radiology, 2013, 42, 635-647.	2.0	110
42	The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma. Histopathology, 2016, 69, 121-127.	2.9	109
43	Recurrent rearrangements of FOS and FOSB define osteoblastoma. Nature Communications, 2018, 9, 2150.	12.8	106
44	The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. Journal of Pathology, 2011, 223, 336-346.	4.5	102
45	Detection of Î²-Catenin Mutations in Paraffin-embedded Sporadic Desmoid-type Fibromatosis by Mutation-specific Restriction Enzyme Digestion (MSRED): an Ancillary Diagnostic Tool. American Journal of Surgical Pathology, 2007, 31, 1299-1309.	3.7	99
46	Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. Journal of Pathology, 2015, 237, 363-378.	4.5	98
47	Comparative methylome analysis of benign and malignant peripheral nerve sheath tumors. Genome Research, 2011, 21, 515-524.	5.5	94
48	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	2.9	90
49	A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma. Cancer Discovery, 2015, 5, 920-931.	9.4	88
50	GNAS1 mutations occur more commonly than previously thought in intramuscular myxoma. Modern Pathology, 2009, 22, 718-724.	5.5	86
51	Processed pseudogenes acquired somatically during cancer development. Nature Communications, 2014, 5, 3644.	12.8	86
52	Hypoxia stimulates osteoclast formation from human peripheral blood. Cell Biochemistry and Function, 2010, 28, 374-380.	2.9	85
53	An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma. Journal of Pathology, 2012, 228, 274-285.	4.5	83
54	Differential Gene Expression in Ovarian Tumors Reveals Dusp 4 and Serpina 5 As Key Regulators for Benign Behavior of Serous Borderline Tumors. Journal of Clinical Oncology, 2005, 23, 7257-7264.	1.6	82

#	Article	IF	Citations
55	Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways. Cancer Cell, 2019, 35, 441-456.e8.	16.8	82
56	Detection of USP6 gene rearrangement in nodular fasciitis: an important diagnostic tool. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 97-98.	2.8	80
57	Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway. Cancer Research, 2015, 75, 3823-3831.	0.9	73
58	EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen. Journal of Pathology, 2016, 239, 320-334.	4.5	73
59	<scp>ERBB</scp>4 confers metastatic capacity in Ewing sarcoma. EMBO Molecular Medicine, 2013, 5, 1087-1102.	6.9	71
60	Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. Genome Research, 2015, 25, 814-824.	5.5	69
61	Synovial chondromatosis and soft tissue chondroma: extraosseous cartilaginous tumor defined by FN1 gene rearrangement. Modern Pathology, 2019, 32, 1762-1771.	5.5	67
62	An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing. Genes Chromosomes and Cancer, 2019, 58, 88-99.	2.8	67
63	Suppression of Deacetylase SIRT1 Mediates Tumor-Suppressive NOTCH Response and Offers a Novel Treatment Option in Metastatic Ewing Sarcoma. Cancer Research, 2014, 74, 6578-6588.	0.9	66
64	Frequency of Mouse Double Minute 2 (MDM2) and Mouse Double Minute 4 (MDM4) amplification in parosteal and conventional osteosarcoma subtypes. Histopathology, 2012, 60, 357-359.	2.9	65
65	Nonbacterial osteitis: a clinical, histopathological, and imaging study with a proposal for protocol-based management of patients with this diagnosis. Journal of Orthopaedic Science, 2009, 14, 505-516.	1.1	61
66	IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas. Histopathology, 2012, 60, 363-365.	2.9	60
67	Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations. Oncotarget, 2016, 7, 5273-5288.	1.8	60
68	Injury Signals Cooperate with Nf1 Loss to Relieve the Tumor-Suppressive Environment of Adult Peripheral Nerve. Cell Reports, 2013, 5, 126-136.	6.4	57
69	Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neoâ€adjuvant chemotherapy. Cancer Medicine, 2014, 3, 980-987.	2.8	57
70	A Reappraisal of Hemangiopericytoma of Bone; Analysis of Cases Reclassified as Synovial Sarcoma and Solitary Fibrous Tumor of Bone. American Journal of Surgical Pathology, 2010, 34, 777-783.	3.7	55
71	Screening for Potential Targets for Therapy in Mesenchymal, Clear Cell, and Dedifferentiated Chondrosarcoma Reveals Bcl-2 Family Members and TGFÎ² as Potential Targets. American Journal of Pathology, 2013, 182, 1347-1356.	3.8	53
72	NF1 loss disrupts Schwann cellâ€"axonal interactions: a novel role for semaphorin 4F. Genes and Development, 2008, 22, 3335-3348.	5.9	52

#	Article	IF	Citations
73	Diagnosing an extra-axial chordoma of the proximal tibia with the help of brachyury, a molecule required for notochordal differentiation. Skeletal Radiology, 2007, 36, 59-65.	2.0	51
74	Cobalt from metal-on-metal hip replacements may be the clinically relevant active agent responsible for periprosthetic tissue reactions. Acta Biomaterialia, 2012, 8, 3865-3873.	8.3	50
75	FOS Expression in Osteoid Osteoma and Osteoblastoma. American Journal of Surgical Pathology, 2019, 43, 1661-1667.	3.7	50
76	Atomic force microscopy of collagen structure in bone and dentine revealed by osteoclastic resorption. Ultramicroscopy, 2005, 105, 79-89.	1.9	49
77	Activating mutations in the MAPâ€kinase pathway define nonâ€ossifying fibroma of bone. Journal of Pathology, 2019, 248, 116-122.	4.5	49
78	Pseudomyogenic (epithelioid sarcoma-like) hemangioendothelioma: characterization of five cases. Skeletal Radiology, 2013, 42, 947-957.	2.0	48
79	GNAS mutations are not detected in parosteal and low-grade central osteosarcomas. Modern Pathology, 2015, 28, 1336-1342.	5.5	47
80	Molecular Genetic Evidence for Monoclonal Origin of Bilateral Ovarian Serous Borderline Tumors. American Journal of Pathology, 2003, 162, 1095-1101.	3.8	44
81	A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma. Clinical Sarcoma Research, 2015, 5, 13.	2.3	44
82	Upregulation of osteoclast Î±2Î²1 integrin compensates for lack of Î±vÎ²3 vitronectin receptor in Iraqi-Jewish-type Glanzmann thrombasthenia. British Journal of Haematology, 2003, 122, 950-957.	2.5	42
83	Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas. Modern Pathology, 2009, 22, 996-1005.	5.5	40
84	Giant Cell Lesions of the Craniofacial Bones. Head and Neck Pathology, 2014, 8, 445-453.	2.6	40
85	Is conservative treatment for adenocarcinoma in situ of the cervix safe?. British Journal of Obstetrics and Gynaecology, 2001, 108, 1184-1189.	0.9	39
86	Frequent alterations in p16/CDKN2A identified by immunohistochemistry and FISH in chordoma. Journal of Pathology: Clinical Research, 2020, 6, 113-123.	3.0	39
87	HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis. Journal of Clinical Investigation, 2020, 130, 3848-3864.	8.2	38
88	Update on the biologic effects of macrophage colony-stimulating factor. Current Opinion in Hematology, 1998, 5, 181-185.	2.5	37
89	High-resolution Whole-Genome Analysis of Skull Base Chordomas Implicates FHIT Loss in Chordoma Pathogenesis. Neoplasia, 2012, 14, 788-IN4.	5.3	37
90	Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 217-222.	2.8	37

#	Article	IF	Citations
91	Mutations in SH3BP2, the cherubism gene, were not detected in central or peripheral giant cell tumours of the jaw. British Journal of Oral and Maxillofacial Surgery, 2008, 46, 229-230.	0.8	35
92	Study of the Nonresorptive Phenotype of Osteoclast-like Cells from Patients with Malignant Osteopetrosis: A New Approach to Investigating Pathogenesis. Journal of Bone and Mineral Research, 2010, 15, 352-360.	2.8	35
93	PRDM10-rearranged Soft Tissue Tumor. American Journal of Surgical Pathology, 2019, 43, 504-513.	3.7	35
94	Next-generation sequencing is highly sensitive for the detection of beta-catenin mutations in desmoid-type fibromatoses. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 203-210.	2.8	34
95	Allelotype of Uterine Leiomyomas. Cancer Genetics and Cytogenetics, 1999, 114, 89-95.	1.0	33
96	Soft tissue angiofibroma: Clinicopathologic, immunohistochemical and molecular analysis of 14 cases. Genes Chromosomes and Cancer, 2017, 56, 750-757.	2.8	33
97	Inhibition of Histone H3K27 Demethylases Inactivates Brachyury (TBXT) and Promotes Chordoma Cell Death. Cancer Research, 2020, 80, 4540-4551.	0.9	33
98	Generation of human osteoclasts in stromal cell-free and stromal cell-rich cultures: differences in osteoclast CD11c/CD18 integrin expression. British Journal of Haematology, 2001, 112, 430-437.	2.5	32
99	Familial tumoral calcinosis and hyperostosisâ€“hyperphosphataemia syndrome are different manifestations of the same disease: novel missense mutations in GALNT3. Skeletal Radiology, 2010, 39, 63-68.	2.0	32
100	Genomeâ€wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. International Journal of Cancer, 2018, 142, 1594-1601.	5.1	31
101	Osteoclasts are present in the giant cell variant of malignant fibrous histiocytoma. Journal of Pathology, 1989, 159, 53-57.	4.5	27
102	Investigation of Ethnic Neutropenia by Assessment of Bone Marrow Colony-Forming Cells. Acta Haematologica, 2001, 105, 32-37.	1.4	26
103	IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation. Scientific Reports, 2016, 6, 27569.	3.3	26
104	Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection. Cancer Medicine, 2017, 6, 2194-2202.	2.8	26
105	Bronchopulmonary and Mediastinal Leishmaniasis: An Unusual Clinical Presentation of Leishmania donovani Infection. Clinical Infectious Diseases, 2000, 30, 764-769.	5.8	25
106	<scp>DNA</scp> methylationâ€based profiling of bone and soft tissue tumours: a validation study of the â€˜<scp>DKFZ</scp> Sarcoma Classifierâ€™. Journal of Pathology: Clinical Research, 2021, 7, 350-360.	3.0	25
107	Undifferentiated pleomorphic sarcomas with PRDM10 fusions have a distinct gene expression profile. Journal of Pathology, 2019, 249, 425-434.	4.5	23
108	Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics. Genome Medicine, 2014, 6, 116.	8.2	22

#	Article	IF	Citations
109	Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia. American Journal of Human Genetics, 2015, 97, 837-847.	6.2	22
110	Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing. Journal of Physical Education and Sports Management, 2018, 4, a002279.	1.2	21
111	Drivers underpinning the malignant transformation of giant cell tumour of bone. Journal of Pathology, 2020, 252, 433-440.	4.5	21
112	<scp>H3K27me3</scp> expression and methylation status in histological variants of malignant peripheral nerve sheath tumours. Journal of Pathology, 2020, 252, 151-164.	4.5	20
113	Sarcoma and the 100,000 Genomes Project: our experience and changes to practice. Journal of Pathology: Clinical Research, 2020, 6, 297-307.	3.0	20
114	A novel next generation sequencing approach to improve sarcoma diagnosis. Modern Pathology, 2020, 33, 1350-1359.	5.5	20
115	Podoplanin expression in adamantinoma of long bones and osteofibrous dysplasia. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 41-46.	2.8	19
116	Benefits of molecular pathology in the diagnosis of musculoskeletal disease. Skeletal Radiology, 2010, 39, 213-224.	2.0	17
117	Limited Rescue of Osteoclast-Poor Osteopetrosis After Successful Engraftment by Cord Blood From an Unrelated Donor. Journal of Bone and Mineral Research, 2005, 20, 2264-2270.	2.8	16
118	Genomics of MPNST (GeM) Consortium: Rationale and Study Design for Multi-Omic Characterization of NF1-Associated and Sporadic MPNSTs. Genes, 2020, 11, 387.	2.4	16
119	Image-guided percutaneous biopsy of intramedullary lytic bone lesions: utility of aspirated blood clots. European Radiology, 2006, 16, 2120-2125.	4.5	15
120	Myopericytoma in Kagerâ€™s fat pad. Skeletal Radiology, 2006, 36, 165-169.	2.0	15
121	Primary Myxoid Liposarcoma of the Ovary in an Adolescent Girl: A Case Report. International Journal of Gynecological Pathology, 2010, 29, 256-259.	1.4	15
122	A diagnostic approach to bone tumours. Pathology, 2017, 49, 675-687.	0.6	15
123	Dedifferentiated Chondrosarcoma Demonstrating Osteosarcomatous Differentiation. Oncology Research and Treatment, 2018, 41, 456-460.	1.2	14
124	Overlapping morphological, immunohistochemical and genetic features of superficial CD34-positive fibroblastic tumor and PRDM10-rearranged soft tissue tumor. Modern Pathology, 2022, 35, 767-776.	5.5	14
125	Generating Human Osteoclasts In Vitro from Bone Marrow and Peripheral Blood. , 2003, 80, 113-128.		13
126	Clear cell sarcoma of the mediastinum. Annals of Diagnostic Pathology, 2009, 13, 197-200.	1.3	13

#	Article	IF	Citations
127	Ovarian cellular fibroma harbouring an isocitrate dehydrogenase 1 (1<scp>DH</scp>1) mutation in a patient with Ollier disease: evidence for a causal relationship. Histopathology, 2013, 62, 667-670.	2.9	13
128	Post-translational regulation contributes to the loss of LKB1 expression through SIRT1 deacetylase in osteosarcomas. British Journal of Cancer, 2017, 117, 398-408.	6.4	13
129	Subperiosteal hemangioendothelioma of the femur. Skeletal Radiology, 2006, 35, 793-796.	2.0	12
130	<scp>MYC</scp> amplifications are common events in childhood osteosarcoma. Journal of Pathology: Clinical Research, 2021, 7, 425-431.	3.0	12
131	Synovial chondromatosis of the foot presenting with Lisfranc dislocation. Skeletal Radiology, 2005, 34, 736-739.	2.0	11
132	The benefits of molecular pathology in the diagnosis of musculoskeletal disease. Skeletal Radiology, 2010, 39, 105-115.	2.0	10
133	Clinical outcome in patients with peripherallyâ€sited atypical lipomatous tumours and dedifferentiated liposarcoma. Journal of Pathology: Clinical Research, 2015, 1, 106-112.	3.0	9
134	<scp>AZD8055</scp> enhances in vivo efficacy of afatinib in chordomas. Journal of Pathology, 2021, 255, 72-83.	4.5	9
135	Liposarcomatous differentiation in malignant peripheral nerve sheath tumor: A case report. Pathology Research and Practice, 2010, 206, 138-142.	2.3	8
136	Analysis of giant cell tumour of bone cells for Noonan syndrome/Cherubismâ€related mutations. Journal of Oral Pathology and Medicine, 2013, 42, 95-98.	2.7	8
137	Chiari I malformation associated with Gorham's disease of the skull base. Clinical Neurology and Neurosurgery, 2014, 116, 83-86.	1.4	8
138	Osteosarcoma: Novel prognostic biomarkers using circulating and cell-free tumour DNA. European Journal of Cancer, 2022, 168, 1-11.	2.8	8
139	Assessment of integrase interactor 1 (INIâ€1) expression in primary tumours of bone. Histopathology, 2012, 61, 1245-1247.	2.9	7
140	Assessment of <scp>MUC</scp>4 expression in primary bone tumours. Histopathology, 2013, 63, 142-143.	2.9	7
141	Systematic Review of Clinical, Radiologic, and Histologic Features of Benign Notochordal Cell Tumors: Implications for Patient Management. World Neurosurgery, 2019, 130, 13-23.	1.3	7
142	Extraâ€axial skeletal poorly differentiated chordoma: a case report. Histopathology, 2020, 76, 924-927.	2.9	7
143	Maffucci syndrome: A genomeâ€wide analysis using high resolution single nucleotide polymorphism and expression arrays on four cases. Genes Chromosomes and Cancer, 2011, 50, 673-679.	2.8	6
144	Notochordal Tumors. Surgical Pathology Clinics, 2021, 14, 619-643.	1.7	6

#	Article	IF	Citations
145	A pan-cancer landscape of somatic mutations in non-unique regions of the human genome. Nature Biotechnology, 2021, 39, 1589-1596.	17.5	6
146	Clear Cell Sarcoma of the Distal Tibialis Posterior Tendon Insertion: A Case Report. Foot and Ankle International, 2008, 29, 445-448.	2.3	4
147	Categorization of cancer through genomic complexity could guide research and management strategies. Journal of Pathology, 2015, 236, 397-402.	4.5	4
148	EWSR1-SMAD3 fibroblastic tumour of bone: expanding the clinical spectrum. Skeletal Radiology, 2021, 50, 445-450.	2.0	4
149	Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with IDH1/2 and GNAS mutations. Molecular Oncology, 2021, 15, 3679-3690.	4.6	4
150	Benign Bone-Forming Tumors. Surgical Pathology Clinics, 2021, 14, 549-565.	1.7	4
151	Optimizing CRISPR/Cas9 Editing of Repetitive Single Nucleotide Variants. Frontiers in Genome Editing, 0, 4, .	5.2	4
152	P63 does not regulate brachyury expression in human chordomas and osteosarcomas. Histopathology, 2011, 59, 1025-1027.	2.9	2
153	Pathology of paediatric bone tumours. Surgery, 2017, 35, 2-9.	0.3	2
154	Radiological Features of Giant Cell Tumours of Bone. Cureus, 2020, 12, e8793.	0.5	2
155	Osteoclast-rich lesions of bone: a clinical and molecular overview. , 2015, , 257-272.		1
156	RARE-29. AZD8055 ENHANCES IN VIVO EFFICACY OF AFATINIB IN CHORDOMAS. Neuro-Oncology, 2019, 21, vi227-vi227.	1.2	1
157	An overview and update on soft tissue lesions of the head and neck. Diagnostic Histopathology, 2021, 27, 171-181.	0.4	1
158	An overview and update on bone lesion in craniofacial bones. Diagnostic Histopathology, 2021, 27, 216-225.	0.4	1
159	Comorbidities and Pregnancy Do Not Affect Local Recurrence in Patients With Giant Cell Tumour of Bone. Cureus, 2020, 12, e9164.	0.5	1
160	Alternative tissue fixation for combined histopathological and molecular analysis in a clinically representative setting. Histochemistry and Cell Biology, 2021, 156, 595-607.	1.7	1
161	Osteoclast-rich Lesions of Bone. , 2010, , 211-224.		0
162	Mutations in <scp>IDH</scp>1 and <scp>IDH</scp>2 are not present in sporadic ovarian sex cordâ€“stromal tumours. Histopathology, 2015, 66, 897-898.	2.9	0

#	Article	IF	Citations
163	Molecular testing of sarcomas. Diagnostic Histopathology, 2017, 23, 431-441.	0.4	0
164	Osteoclast-rich lesions of bone. , 2022, , 631-647.		0